Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients

類似資料

• Clinical translation of theranostic radiopharmaceuticals: Current regulatory status and recent examples
  著者:: Kolenc Peitl, Petra, 等
  出版事項: (2019)
• From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial
  著者:: Pawlak, Dariusz, 等
  出版事項: (2016)
• A novel CCK(2)/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study
  著者:: Erba, Paola A., 等
  出版事項: (2018)
• Selection of the First (99m)Tc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation—Preclinical Assessment of Two Optimized Candidates
  著者:: Fani, Melpomeni, 等
  出版事項: (2020)
• Comparative biodistribution of 12 (111)In-labelled gastrin/CCK2 receptor-targeting peptides
  著者:: Laverman, Peter, 等
  出版事項: (2011)